New England Journal of Medicine
December 5, 2019 Vol. 381 No. 23
http://www.nejm.org/toc/nejm/medical-journal

Original Articles
Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal
Mila Shakya, M.P.H., and others for the TyVAC Nepal Study Team*
Salmonella Typhi is a major cause of fever in children in low- and middle-income countries. A typhoid conjugate vaccine (TCV) that was recently prequalified by the World Health Organization was shown to be efficacious in a human challenge model, but data from efficacy trials in areas where typhoid is endemic are lacking.